TapewireFind a company

person · Reporting owner

THURMAN RANDY H

Disclosed activity across 4 companies

Tapewire entity
43781
SEC CIK
0001204059

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Outlook Therapeutics, Inc.OTLK · Entity 608DirectorMay 26, 2026May 27, 2026
Presbia PLCLENS · Entity 160670Director · Executive ChairmanMarch 13, 2017March 22, 2017
TFF Pharmaceuticals, Inc.TFFP · Entity 89110DirectorSeptember 29, 2022September 30, 2022
Veradigm Inc.MDRX · Entity 13670DirectorMay 22, 2017May 24, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Outlook Therapeutics, Inc.

Report date May 26, 2026 · Filed May 27, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect5,593 Reported balance After 2026-05-26 transaction · row 1
1 source row

Row 1 · 2026-05-26 · Purchase · Acquired 5,000 · Balance 5,593

Presbia PLC

Report date March 13, 2017 · Filed March 22, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect45,924 Reported balance After 2017-03-13 transaction · row 1
1 source row

Row 1 · 2017-03-13 · Grant · Acquired 12,738 · Balance 45,924

F1: On March 13, 2017, the Reporting Person was granted 12,738 restricted ordinary shares, which vest on March 13, 2018.

Ordinary SharesSEC Table I · non-derivativeIndirectBy Ralph H. Thurman Rev Trust1,833 Reported balance Holding disclosure · report date 2017-03-13 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 1,833

F2: The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: On March 13, 2017, the Reporting Person was granted 12,738 restricted ordinary shares, which vest on March 13, 2018.

F2: The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

TFF Pharmaceuticals, Inc.

Report date September 29, 2022 · Filed September 30, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Ending reported balance After 2022-09-29 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2022-09-29 · Exercise / conversion · Acquired 40,255 · Balance 40,255

Row 2 · 2022-09-29 · Sale · Disposed 40,255 · Balance 0

F1: The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2029-04-11Direct84,670 Reported balance After 2022-09-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2022-09-29 · Exercise / conversion · Disposed 40,255 · Balance 84,670

F2: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.

Filing footnotes · ownership attribution and instrument terms

F1: The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

F2: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.

Veradigm Inc.

Report date May 22, 2017 · Filed May 24, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect105,014 Reported balance After 2017-05-22 transaction · row 1
1 source row

Row 1 · 2017-05-22 · Grant · Acquired 16,765 · Balance 105,014

F1: Restricted stock units award with vesting that will occur in twelve (12) equal monthly installments, commencing in June 2017. Distribution of the vested units is deferred pursuant to the Allscripts Healthcare Solutions, Inc. Director Deferred Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units award with vesting that will occur in twelve (12) equal monthly installments, commencing in June 2017. Distribution of the vested units is deferred pursuant to the Allscripts Healthcare Solutions, Inc. Director Deferred Compensation Plan.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 26, 2026 Filed May 27, 2026 19:20 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 5,000 $0.43 $2,145.00
Disclosure

SEC source: 0001649989-26-000002 · primary_doc.xml · nonDerivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,593

Read SEC document
October 01, 2025 Filed Oct 3, 2025 23:00 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 286,734 $0.00 Strike: $1.04 $0.00
Disclosure

SEC source: 0001649989-25-000004 · primary_doc.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 286,734

Underlying: Common Stock · 286,734 shares

Expires 2035-10-01

F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
October 01, 2024 Filed Oct 4, 2024 00:30 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 89,549 $0.00 Strike: $5.22 $0.00
Disclosure

SEC source: 0001415889-24-024701 · form4-10032024_081001.xml · derivative · entry 2

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,549

Underlying: Common Stock · 89,549 shares

Expires 2034-10-01

F2 · derivative.exercise_date: This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
October 01, 2024 Filed Oct 4, 2024 00:30 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 56,636 $0.00 Strike: $5.22 $0.00
Disclosure

SEC source: 0001415889-24-024701 · form4-10032024_081001.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,636

Underlying: Common Stock · 56,636 shares

Expires 2034-10-01

F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 21:04 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 94,441 $0.00 Strike: $0.41 $0.00
Disclosure

SEC source: 0001415889-24-007319 · form4-03082024_090322.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,441

Underlying: Common Stock · 94,441 shares

Expires 2034-03-07

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
March 29, 2023 Filed Mar 31, 2023 21:44 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 41,065 $0.00 Strike: $1.05 $0.00
Disclosure

SEC source: 0001209191-23-021905 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,065

Underlying: Common Stock · 41,065 shares

Expires 2033-03-29

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
September 29, 2022 Filed Sep 30, 2022 21:20 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 Exercise / conversionStock Options (Right to Buy) · Derivative 40,255 $0.00 Strike: $2.50 $0.00
Disclosure

SEC source: 0001213900-22-060782 · ownership.xml · derivative · entry 3

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,670

Underlying: Common Stock · 40,255 shares

Expires 2029-04-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.

Read SEC document
September 29, 2022 Filed Sep 30, 2022 21:20 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 SaleCommon Stock 40,255 $4.29 $172,693.95
Disclosure

SEC source: 0001213900-22-060782 · ownership.xml · nonDerivative · entry 2

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

F1 · price: The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

Read SEC document
September 29, 2022 Filed Sep 30, 2022 21:20 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 Exercise / conversionCommon Stock 40,255 $2.50 $100,637.50
Disclosure

SEC source: 0001213900-22-060782 · ownership.xml · nonDerivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 23, 2022 Filed Mar 24, 2022 21:36 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 81,878 $0.00 Strike: $1.92 $0.00
Disclosure

SEC source: 0001209191-22-020949 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,878

Underlying: Common Stock · 81,878 shares

Expires 2032-03-23

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 23,2023; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
May 18, 2021 Filed May 19, 2021 20:05 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 PurchaseCommon Stock 1,050 $9.40 $9,870.00
Disclosure

SEC source: 0001213900-21-027899 · ownership.xml · nonDerivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,050

Read SEC document
March 24, 2021 Filed Mar 26, 2021 22:06 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 20,873 $0.00 Strike: $2.27 $0.00
Disclosure

SEC source: 0001209191-21-023279 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,873

Underlying: Common Stock · 20,873 shares

Expires 2031-03-24

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
November 13, 2020 Filed Nov 14, 2020 02:01 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 SaleCommon Stock 5,000 $17.17 $85,865.00
Disclosure

SEC source: 0001213900-20-037060 · ownership.xml · nonDerivative · entry 3

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Read SEC document
November 11, 2020 Filed Nov 14, 2020 02:01 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 Exercise / conversionStock Options (Right to Buy) · Derivative 34,504 $0.00 Strike: $2.50 $0.00
Disclosure

SEC source: 0001213900-20-037060 · ownership.xml · derivative · entry 4

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,925

Underlying: Common Stock · 34,504 shares

Expires 2029-04-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.

F2 · derivative.exercise_date: 23,003 shares of common stock vested on April 11, 2020 and the remainder of shares scheduled to vest at an approximate rate of 5,750 every three months thereafter.

Read SEC document
November 11, 2020 Filed Nov 14, 2020 02:01 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 SaleCommon Stock 34,504 $15.91 $548,889.63
Disclosure

SEC source: 0001213900-20-037060 · ownership.xml · nonDerivative · entry 2

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.

Read SEC document
November 11, 2020 Filed Nov 14, 2020 02:01 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 Exercise / conversionCommon Stock 34,504 $2.50 $86,260.00
Disclosure

SEC source: 0001213900-20-037060 · ownership.xml · nonDerivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,504

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.

Read SEC document
October 05, 2020 Filed Oct 5, 2020 22:44 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 396,809 $0.51 Strike: $0.71 $203,999.51
Disclosure

SEC source: 0001209191-20-053870 · doc4.xml · derivative · entry 2

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 396,809

Underlying: Common Stock · 396,809 shares

Expires 2030-10-05

F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $204,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 22:44 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 259,297 $0.00 Strike: $0.71 $0.00
Disclosure

SEC source: 0001209191-20-053870 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 259,297

Underlying: Common Stock · 259,297 shares

Expires 2030-10-01

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
September 14, 2020 Filed Sep 15, 2020 22:31 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 10,000 $0.62 $6,200.00
Disclosure

SEC source: 0001209191-20-050564 · doc4.xml · nonDerivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,875

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.62 to $0.625, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Reflects a 1-for-8 reverse stock split effected by the Issuer on March 15, 2019 (the "Split Date"). The Reporting Person's previous ownership of 15,000 shares of common stock was adjusted to 1,875 shares of Common Stock on the Split Date.

Read SEC document
August 24, 2020 Filed Aug 26, 2020 22:16 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 GrantStock Options (Right to Buy) · Derivative 20,000 $0.00 Strike: $13.65 $0.00
Disclosure

SEC source: 0001213900-20-023901 · ownership.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,429

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Option shall vest and first become exercisable as follows: one-quarter of the Option shall vest and first become exercisable on August 24, 2021 and the remainder of the Option shall vest and first become exercisable in 12 equal quarterly installments commencing on November 24, 2021.

F1 · derivative.expiration_date: Each Option shall vest and first become exercisable as follows: one-quarter of the Option shall vest and first become exercisable on August 24, 2021 and the remainder of the Option shall vest and first become exercisable in 12 equal quarterly installments commencing on November 24, 2021.

Read SEC document
July 17, 2020 Filed Jul 21, 2020 22:11 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 210,000 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0001209191-20-043228 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Common Stock · 210,000 shares

Expires 2030-07-17

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
July 17, 2020 Filed Sep 17, 2020 23:20 UTC Amendment Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 154,555 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0001209191-20-051048 · doc4a.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,555

Underlying: Common Stock · 154,555 shares

Expires 2030-07-17

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
March 19, 2020 Filed Mar 20, 2020 21:52 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $0.54 $0.00
Disclosure

SEC source: 0001209191-20-020508 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-03-19

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
November 29, 2019 Filed Dec 4, 2019 00:42 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 GrantStock Options (Right to Buy) · Derivative 3,623 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001213900-19-025249 · ownership.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,429

Underlying: Common Stock · 3,623 shares

Expires 2029-10-29

F1 · derivative.exercise_date: 25% of the options vest on the first anniversary of the grant and the remainder vest in equal quarterly installments over the next three years.

Read SEC document
October 29, 2019 Filed Oct 30, 2019 00:32 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 GrantStock Options (Right to Buy) · Derivative 43,794 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001213900-19-021424 · ownership.xml · derivative · entry 2

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,806

Underlying: Common Stock · 43,794 shares

Expires 2029-10-29

F2 · derivative.exercise_date: 25% of the options vest on the first anniversary of the grant and the remainder vest in equal quarterly installments over the next three years.

Read SEC document
October 25, 2019 Filed Oct 30, 2019 00:32 UTC TFF Pharmaceuticals, Inc. TFFP · Entity 89110 PurchaseCommon Stock 5,000 $5.00 $25,000.00
Disclosure

SEC source: 0001213900-19-021424 · ownership.xml · nonDerivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: The shares of common stock purchased in the Issuer's initial public offering.

Read SEC document
October 03, 2019 Filed Oct 7, 2019 22:08 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 207,036 $0.99 Strike: $1.40 $203,992.57
Disclosure

SEC source: 0001209191-19-052709 · doc4.xml · derivative · entry 2

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,036

Underlying: Common Stock · 207,036 shares

Expires 2029-10-03

F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $204,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
October 03, 2019 Filed Oct 7, 2019 22:08 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $1.40 $0.00
Disclosure

SEC source: 0001209191-19-052709 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-10-03

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 22:17 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 15,000 $0.68 $10,251.00
Disclosure

SEC source: 0001209191-18-063966 · doc4.xml · nonDerivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63 - $0.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 09, 2018 Filed Nov 13, 2018 21:55 UTC Outlook Therapeutics, Inc. ONS · Entity 608 GrantStock Option (Right to Buy) · Derivative 567,522 $0.61 Strike: $0.89 $347,890.99
Disclosure

SEC source: 0001209191-18-058302 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 567,522

Underlying: Common Stock · 567,522 shares

Expires 2028-11-09

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Plan in lieu of two years of cash retainer and meeting fees, including Executive Chairman fee, of $348,000.

F1 · derivative.exercise_date: Immediately exercisable.

Read SEC document
September 21, 2018 Filed Sep 25, 2018 21:00 UTC Outlook Therapeutics, Inc. ONS · Entity 608 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $0.92 $0.00
Disclosure

SEC source: 0001209191-18-052159 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-09-21

F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on September 21, 2019, subject to the Reporting Person providing continuous service to the Issuer on such date.

Read SEC document
June 27, 2018 Filed Jun 28, 2018 21:19 UTC Outlook Therapeutics, Inc. ONS · Entity 608 GrantStock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-18-039938 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2028-06-27

F1 · derivative.exercise_date: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on June 27, 2021, subject to the Reporting Person providing continued service through such date.

Read SEC document
April 13, 2018 Filed Apr 17, 2018 21:05 UTC Outlook Therapeutics, Inc. ONS · Entity 608 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $0.92 $0.00
Disclosure

SEC source: 0001209191-18-025216 · doc4.xml · derivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-04-13

F1 · derivative.exercise_date: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on April 13, 2021, subject to the Reporting Person providing continued service through such date.

Read SEC document
May 22, 2017 Filed May 24, 2017 20:45 UTC Veradigm Inc. MDRX · Entity 13670 GrantCommon Stock 16,765 $0.00 $0.00
Disclosure

SEC source: 0001209191-17-035000 · doc4.xml · nonDerivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,014

F1 · kind: Restricted stock units award with vesting that will occur in twelve (12) equal monthly installments, commencing in June 2017. Distribution of the vested units is deferred pursuant to the Allscripts Healthcare Solutions, Inc. Director Deferred Compensation Plan.

Read SEC document
March 13, 2017 Filed Mar 22, 2017 21:01 UTC Presbia PLC LENS · Entity 160670 GrantOrdinary Shares 12,738 $0.00 $0.00
Disclosure

SEC source: 0000905718-17-000378 · thurman_fm4mar132017.xml · nonDerivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,924

F1 · shares: On March 13, 2017, the Reporting Person was granted 12,738 restricted ordinary shares, which vest on March 13, 2018.

Read SEC document
March 08, 2017 Filed Mar 10, 2017 21:05 UTC Presbia PLC LENS · Entity 160670 OtherSubscription Rights (right to buy) · Derivative 16,533 $0.00 Strike: $3.00 $0.00
Disclosure

SEC source: 0000905718-17-000331 · thurman_fm4mar102017.xml · derivative · entry 3

THURMAN RANDY H · CIK 0001204059 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 5,543 shares

Expires 2017-03-08

F3 · shares: Each subscription right entitled its holder to purchase 0.335297256 Ordinary Shares at a subscription price of $3.00 per whole Ordinary Share.

Read SEC document
March 08, 2017 Filed Mar 10, 2017 21:05 UTC Presbia PLC LENS · Entity 160670 OtherOrdinary Shares 5,543 $3.00 $16,629.00
Disclosure

SEC source: 0000905718-17-000331 · thurman_fm4mar102017.xml · nonDerivative · entry 1

THURMAN RANDY H · CIK 0001204059 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,186

F1 · shares: On March 8, 2017, the Reporting Person delivered to the Issuer an irrevocable notice of exercise of his subscription rights to purchase 5,543 Ordinary Shares, together with payment of the requisite fee, pursuant to the rights offering set forth in the Prospectus filed pursuant to Rule 424(b)(4), filed with the SEC on January 27, 2017, as amended February 23, 2017.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.